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Abstract
Antimicrobial resistance in Staphylococcus aureus is a major public health threat, compounded by emergence of strains with
resistance to vancomycin and daptomycin, both last line antimicrobials. Here we have performed high throughput DNA
sequencing and comparative genomics for five clinical pairs of vancomycin-susceptible (VSSA) and vancomycin-
intermediate ST239 S. aureus (VISA); each pair isolated before and after vancomycin treatment failure. These comparisons
revealed a frequent pattern of mutation among the VISA strains within the essential walKR two-component regulatory locus
involved in control of cell wall metabolism. We then conducted bi-directional allelic exchange experiments in our clinical
VSSA and VISA strains and showed that single nucleotide substitutions within either walK or walR lead to co-resistance to
vancomycin and daptomycin, and caused the typical cell wall thickening observed in resistant clinical isolates. Ion Torrent
genome sequencing confirmed no additional regulatory mutations had been introduced into either the walR or walK VISA
mutants during the allelic exchange process. However, two potential compensatory mutations were detected within
putative transport genes for the walK mutant. The minimal genetic changes in either walK or walR also attenuated virulence,
reduced biofilm formation, and led to consistent transcriptional changes that suggest an important role for this regulator in
control of central metabolism. This study highlights the dramatic impacts of single mutations that arise during persistent
S. aureus infections and demonstrates the role played by walKR to increase drug resistance, control metabolism and alter the
virulence potential of this pathogen.
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Introduction
In hospitals worldwide infections with methicillin-resistant S.
aureus (MRSA) remain a significant cause of morbidity and
mortality, with a small number of clones accounting for a large
number of hospital acquired infections. In Australasia, multi-locus
sequence type (MLST) 239 (ST239) is the major hospital acquired
clone of MRSA, and has been present in the region for over 30
years. This clone is resistant to almost all antibiotic classes;
therefore the mainstay of therapy for serious MRSA infections has
been the glycopeptide antibiotic vancomycin. However, resistant
strains have recently emerged [1], and although the level of
resistance is low there is an impact on treatment outcome [2].
These vancomycin-intermediate S. aureus (VISA, vancomycin MIC
4–8 mg/ml) and heterogenous-VISA (hVISA, vancomycin MIC
#2 mg/ml with a ‘‘resistant subpopulation’’) strains are increas-
ingly common, however the genetics of resistance are incompletely
defined [3]. While the emergence of VISA in Australia has been in
strains of the ST239 clone [4], the first VISA strain Mu50 was
reported from Japan in 1997 [5], and a number of other reported
VISA strains belong to the same clonal complex as Mu50 (CC5)
[6–8].
In many cases VISA emerge from fully-vancomycin susceptible
S. aureus (VSSA) parental strains during persistent infection [6,8,9],
and in some cases this has been associated with the evolution of
daptomycin non-susceptibility despite the absence of exposure to
daptomycin [10]. VISA strains appear to arise via sequential point
mutations in key staphylococcal regulatory genes [11–13],
however the breadth of mutations that can contribute to resistance
are poorly defined. In addition, it is not clear if there are
differences in resistance mechanisms and pathways to VISA in
different clones of S. aureus. Commonly described phenotypic
changes in VISA compared to VSSA include increased cell wall
thickness and reduced autolytic activity [7,14,15], in addition to
other significant phenotypic changes that are predicted to impact
the virulence of the organism. These include a reduction in biofilm
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enhanced capsule production [3,4,15,16]. The link(s) between
development of antimicrobial resistance and the regulation of
these virulence factors is unknown.
A number of studies have used comparative genomics of paired
S. aureus isolates to detect mutations that occur in the resistant
strain compared to the parent strain, including a landmark study
by Mwangi et al where increasing vancomycin resistance in
sequential clinical isolates of S. aureus were linked to accumulated
mutations in the increasingly resistant strain [11]. However, the
genetic loci where mutations in clinical S. aureus strains have been
experimentally confirmed using allelic replacement experiments to
contribute to VISA are limited to vraSR, graRS, and more recently
rpoB [13,17,18]. We have previously used functional genomics to
show that a point mutation in graS can lead to reduced
vancomycin susceptibility in one clinical pair of ST239 VSSA
(JKD6009) and VISA (JKD6008) [18]. However this mutation,
while leading to a reduction in vancomycin susceptibility, did not
restore the full VISA resistance profile. It is worth noting that all
these studies have focussed on a total of three clinical and
laboratory induced VISA isolates, and screening of additional
ST239 VISA strains has failed to demonstrate that mutations in
these loci are common to other VISA [4], suggesting that there are
mutations in as yet undefined loci contributing to VISA in other
clinical isolates.
Daptomycin is an antibiotic that exerts its effect at the cell
membrane, and while a link between VISA and daptomycin non-
susceptibility has been demonstrated [10,19], the genetics of this
relationship are undefined. While mutations in mprF, rpoB and rpoC
are thought to be the genetic basis for daptomycin non-
susceptibility in S. aureus, mutations have also been detected in
walK [20]. The contribution of the walK mutations to daptomycin
non-susceptibility has not been defined as these strains also
harboured mprF mutations.
To expand understanding of the mechanisms of VISA and
identify other loci contributing to vancomycin resistance we fully
sequenced four additional clinical pairs of VSSA and VISA, and
then compared them to the fully assembled and annotated genome
of our previously described VISA strain JKD6008 [21]. We also
re-analyzed our original sequenced pair (JKD6008 and JKD6009)
after fully assembling the genome sequence of the VISA strain
JKD6008. Using this approach, followed by allelic replacement
experiments, we show that WalKR (also known as YycGF and
VicKR) plays a major role during the in vivo evolution of extensive
drug resistance in clinical S. aureus. Our findings highlight an
unexpected degree of plasticity within this essential two-compo-
nent regulator and are particularly pertinent, with inhibitors of
WalK recently proposed as novel anti-staphylococcal agents [22–
24].
Results
Isolate Selection and Characteristics
To identify the genetic mechanisms leading to VISA five clinical
pairs of VSSA and VISA were selected, where the resistant strain
evolved from the susceptible parent strain during failed vancomy-
cin therapy [15,18]. In addition, we also examined eight global
non-paired hVISA and VISA (Table 1). The clinical pairs were
selected from patients that had been treated with vancomycin, and
not daptomycin. This meant that any changes in daptomycin
susceptibility linked to vancomycin exposure and increasing
vancomycin resistance could be specifically assessed. The duration
of in vivo vancomycin exposure ranged from 8 to 42 days in these
clinical isolate pairs and the majority of isolates fulfilled the criteria
for VISA (vancomycin broth MIC 4–8 mg per ml). For all VISA
strains in the isolate pairs an increase in daptomycin MIC was seen
compared to the parental VSSA strain, and five of the 13 hVISA/
VISA isolates were daptomycin non-susceptible (Table 1). All of
the clinical strains were typed using the StaphyType96 DNA
Array (CLONDIAG, Jena, Germany) to predict the sequence
type, mec type, and agr type (Table 1). All of the clinical pairs were
from Australia and New Zealand, and were ST239 MRSA, the
dominant hospital clone of MRSA in the region, while the
additional isolates represented a range of staphylococcal sequence
types within clonal complexes 5 and 8.
Genome Comparisons Highlight Mutations in walKR
Associated with Reduced Vancomycin and Daptomycin
Susceptibility in S. aureus
In an earlier study of the VSSA/VISA pair JKD6009/
JKD6008 we compared partially assembled 454 GS20 sequences
and found six nucleotide substitutions in JKD6008 [18]. We then
showed that a mutation occurring in the sensor region of the graS
gene partly explained the reduced vancomycin susceptibility of this
strain. To now comprehensively address the question of mutations
that contribute to VISA we used our recently completed JKD6008
reference genome [21] which we have shown is closely related to
other Australasian ST239 strains (unpublished data), and is
therefore an appropriate reference genome for analysis, and used
our read-mapping technique to re-examine the genetic differences
between JKD6008 and JKD6009 as well as comparing four other
clinical VSSA/VISA pairs (Table 1, strain pairs 1, 2, 4 and 5).
Using either SOLiD or Illumina technologies, high coverage short-
read sequences were obtained for the clinical pairs with high mean
fold coverage (JKD6009 [SOLiD] mean fold coverage 338.7x;
other strains [Illumina] mean fold coverage 85.5 to 230.6x). The
list of differences between JKD6009 and JKD6008 increased from
six to 10, but each pair presented a limited list of mutations in the
VISA strain compared to its VSSA parent (Table 2). The most
interesting observation was the presence of a previously undetect-
ed SNP in the walK gene of JKD6008. Strikingly, three of the four
other clinical pairs also had single mutations within the walKR
locus (Table 2). In one pair (JKD6004/JKD6005), the only
Author Summary
The treatment of serious infections caused by Staphylo-
coccus aureus is complicated by the development of
antibiotic resistance, and recently resistance to one of the
last available antibiotics to treat resistant S. aureus
infections, vancomycin, has also emerged. Here we have
shown using whole genome sequencing of 10 S. aureus
strains and gene replacement experiments on sequential
S. aureus isolates obtained during persistent bloodstream
infection, how S. aureus evolved intermediate vancomycin
resistance by acquiring mutations in the important
regulator WalKR. Mutations in this locus were found to
be common in strains of S. aureus demonstrating
intermediate vancomycin resistance, and these strains also
demonstrated daptomycin non-susceptibility even though
this drug had never been used for treatment. Experiments
to replace the mutated walK or walR into the parent strain
and vice versa confirmed that these mutations were
responsible for the antibiotic resistance, but also led to
significant changes in virulence, biofilm formation, and
regulation of metabolism within the organism. This study
highlights the adaptability of S. aureus in the face of
antimicrobial treatment.
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Isolate
Pair and
Mutation
no.
Mutation
in VISA
(Sa_JKD6008
coordinate)
Locus
(Sa_JKD6008) Gene Function
Effect of
Mutation
Pair 1 - JKD6000/
JKD6001
1 G to A (24673) SAA6008_00018 walR Response regulator, essential A96T
2 G to A (1217720) Intergenic
3 T to A (2006385) SAA6008_01867 Putative phage protein Q22H
4 G to A (2142758) SAA6008_02029 dUTPase Silent
5 T to G (2142774) SAA6008_02029 dUTPase N2T
SAA6008_02030 acetyltransferase E136D
6 T to C (2150689) Intergenic
7 C to T (2151557) Intergenic
Pair 2 - JKD6004/
JKD6005
1 A to G (25010) SAA6008_00018 walR Response regulator, essential K208R
Pair 3 - JKD6009/
JKD6008
1 G to A (25769) SAA6008_00019 walK Sensor kinase, essential G223D
2 A to G (360905) SAA6008_00313 glpT Glycerol-3-phosphate transporter Silent
3
a C to T (734466) SAA6008_00676 graS T136I
4
a G to A (976097) SAA6008_00920 addA ATP-dependent nuclease subunit A Silent
5
a T to A (1721456) SAA6008_01608 tgt Queuine tRNA-ribosyltransferase F365Y
6 C to T (2391832) Intergenic
7
a C to T (2470905) SAA6008_02357 Sodium/bile acid symporter family protein P128S.
8
a G to A (2754296) SAA6008_02622 Pyridine nucleotide-disulphide reductase G268D
9
a C to T (2846492) Intergenic
10 G to A (2892543) SAA6008_02743 ABC transporter ATP binding protein Silent
Pair 4 - JKD6021/
JKD6023
1 G to T (25903) SAA6008_00019 walK Sensor kinase, essential V268F
2 G to A (57470) SAA6008_00049 Cadmium-transporting ATPase A163T
3 C to T (454602) Intergenic
4 C to A (637292) Intergenic
5 A to T (727814) SAA6008_00669 Hypothetical Protein Premature stop
6 T to C (916693) Intergenic
7 G to A (2022797) Intergenic
8 G to A (2403501) SAA6008_02288 rpsJ 30S ribosomal protein S10 Silent
Pair 5 - JKD6052/
JKD6051
1 C to A (46858) SAA6008_00039 mecA PBP2a A97S
2 C to T (600465) SAA6008_00548 rpoB DNA directed RNA polymerase beta subunit H481Y
3 G to A (849972) SAA6008_00779 trxB Thioredoxin-disulfide reductase A311T
4 T insertion (1015671) SAA6008_00955 CHP Premature stop
5 T to C (1062271) SAA6008_01000 menB Naphthoate synthase Silent
6 C to T (2443041) SAA6008_02331 sarR Staphylococcal accessory regulator R A68T
7 G to A (2892543) SAA6008_02743 ABC transporter ATP binding protein Silent
NB.
aThese mutations were previously detected and described prior to genome closure and re-analysis. VSSA, vancomycin-susceptible S. aureus; VISA, vancomycin-
intermediate S. aureus.
doi:10.1371/journal.ppat.1002359.t002
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JKD6005. JKD6051 was the only VISA strain among the five
sequenced pairs without a walKR mutation. Mutations of potential
interest in this strain included a mutation in the regulator SarR
(A68T), and a mutation in RpoB (H481Y).
Frequency and Role of walKR Mutations in Reduced
Vancomycin and Daptomycin Susceptibility in S. aureus
Given the previous reports of diverse genetic pathways involved
in VISA we were surprised to find a single locus that was mutated
in four of our five pairs of sequenced strains. To extend this
analysis the walKR locus was sequenced from 8 additional,
unpaired global isolates of hVISA/VISA that were available for
study (Table 3). This demonstrated that, in addition to the four
VISA strains in the genome sequencing analysis, 6 of the 8
additional resistant strains also had a mutation in the walKR locus.
The downstream genes yycHIJ are involved in repression of walR
in B. subtilis [25], therefore we sequenced yycHIJ for the two strains
where a mutation in walKR was not detected but no mutations
were found (Table 3).
Analysis of the positions of the mutations within the walKR
genes in this study indicates that they are not limited to a specific
domain or region (Figure 1A). Indeed, the mutations occur across
the spectrum of the domains that contribute to two-component
regulator function. Each change therefore presumably exerts its
effect via distinct mechanisms. For example the WalR A96T
mutation occurs in a conserved region that is important for
phosphorylation-mediated protein conformational changes [26]
(Figure 1B), while the K208R mutation occurs in a highly
conserved a3 DNA recognition helix region (Figure 1B). Recently,
the crystal structure of DNA-binding domain of S. aureus WalR
protein has been solved, and the interaction of the protein with
target DNA examined [27]. Modelling the WalR DNA-binding
domain with the K208R mutation from the VISA strain JKD6005
highlights its proximal location to the critical a3–b5 DNA binding
loop (Figure 1C).
Within WalK, amino acid substitutions were detected in a range
of functional domains (Figure 1), including the G223D mutation in
JKD6008 at a highly conserved residue required for a sharp
reverse turn between the a1 helix and the connector region of the
HAMP domain [28], the 3-amino acid deletion D337–340 in
BPH0191 in the b scaffold of the PAS domain, which is also
known to be involved in its structural integrity [29], and the
N382S mutation in WalK from BPH0073 in the phosphor-
acceptor domain, only 3 amino acids from the conserved histidine
that undergoes autophosphorylation and is essential for autokinase
activity (Figure 1B).
Generation and Whole Genome Sequencing of walKR
Mutants
To measure the impact of these single nucleotide changes in
walKR, bi-directional allelic replacement experiments were per-
formed using two of the clinical pairs (Table 2, pairs 2 and 3). The
walK mutation from VISA strain JKD6008 was introduced into
the parent VSSA JKD6009, generating TPS3130 (Table 4). We
have previously generated a GraS T136I mutation in JKD6009
(JKD6208) [18], therefore to measure the impact of the walK/graS
double mutation, the walK mutation from VISA JKD6008 was
also introduced into the previously produced graS mutant
(JKD6208), generating TPS3128 (Table 4). The walR allele from
the VISA strain JKD6005 was used to replace the walR allele in
the VSSA parent JKD6004 generating TPS3190, and the walR
allele from VSSA parent (JKD6004) was used to replace the walR
allele from VISA strain (JKD6005) generating the vancomycin-
susceptible strain TPS3124 (Table 4).
We next sequenced the genomes of S. aureus mutants TPS3130
and TPS3190 to determine if unintended mutations had been
introduced during the pKOR1-mediated allelic exchange process,
particularly in other regulatory loci such as agr. Coverage of the
reference strain JKD6008 was 99.7% and 96.9% for TPS3130 and
TPS3190, respectively. For strain TPS3190, Ion Torrent sequenc-
ing confirmed the expected walR mutation at position 25010 and
the presence of a single silent mutation in walK at position 26026,
but no other changes. The unintended change at nucleotide 26026
was a PCR-induced error, introduced during cloning in pKOR1.
The situation with strain TPS3130 was more complex. TPS3130,
which is VSSA strain JKD6009 modified by replacing its walK
gene with the allele from VISA strain JKD6008 (conferring the
G223D amino acid change) had the predicted SNP at position
25769 (Figure S1) but also carried an additional four SNPs not
present in JKD6009 (Table 5). Two of these four SNPs were the
same as changes found in VISA strains JKD6008 and we propose
that these might be compensatory mutations linked to the walK
mutation. The probability of these changes occurring by chance at
exactly these positions in JKD6008 and TPS3190 is small
(p,2.3E13) and one can exclude the possibility of a strain mix-
up, as the remaining two SNPs were specific to TPS3130 (Table 5).
PCR and Sanger sequencing confirmed that the sequences at all
five of these altered loci in JKD6009, JKD6008 and TPS3130
were correct.
Impact of walKR Mutations on Antimicrobial Resistance
Vancomycin susceptibility significantly decreased when either
the walK allele from JKD6008 (VISA) or the walR allele from
JKD6005 (VISA) was swapped into its respective VSSA parent
(Table 4 and Figure 2A and B). While the single G223D mutation
in WalK converted the VSSA parent strain JKD6009 to VISA, the
combination of the G223D mutation in WalK and the T136I
mutation in GraS was required to convert JKD6009 to the full
intermediate resistance of JKD6008. In comparison, the single
K208R mutation in WalR from VISA strain JKD6005 was
sufficient to convert JKD6004 (VSSA parent) to intermediate
vancomycin resistance.
The in vivo evolution of VISA occurred without daptomycin
exposure, however an increase in daptomycin MIC was detected
in the majority of VISA strains in this study. Examination of
daptomycin susceptibility in the mutants (Table 4) showed that
Table 3. Screening for walKR mutations in unique (non-
paired) strains.
Isolate
Molecular
Type Phenotype WalK WalR YycHIJ
BPH0191 ST239-III [3A] hVISA, DS del 469-470 ND -
PC3 ST5 – II [2A] VISA, DNS A567D ND -
Sweden 307 ST5 – II [2A] VISA, DNS del 337-340 ND -
VISA 3759 ST247 – I [1B] VISA, DS ND ND ND
BPH0062 ST247 – I [1B] hVISA, DS ND ND ND
BPH0065 ST239-III [3A] VISA, DNS T595I ND -
BPH0073 ST239-III [3A] VISA, DS N382S ND -
BPH0088 ST5 – II [2A] hVISA, DS L14F ND -
Note: DS, daptomycin susceptible; DNS, daptomycin non-susceptible; -, yycHIJ
amplification and sequencing not performed in these strains.
doi:10.1371/journal.ppat.1002359.t003
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single WalR K208R substitution increased the daptomycin MIC
of the parental VSSA strain JKD6004 from 0.5 mg per ml to 2 mg
per ml generating a daptomycin non-susceptible strain (TPS3190),
while the double walK/graS mutant (TPS3128) had a distinct
increase in daptomycin MIC compared to the parental strain,
although it remained within the defined susceptible range.
The Impact of walKR Mutations on Other Recognized
VISA Phenotypes
We next measured autolytic activity and cell wall thickness in
the walKR allele-swapped strains compared to their VSSA and
VISA parents. The impacts of the single substitutions in either
WalR or WalK were dramatic, with significant reductions in
autolytic activity and increases in cell wall thickness linked to the
introduction of the walR or walk allele from the VISA strain into
the VSSA parent (Figure 2C and 3). Conversely, the phenotypes
were reversed when the VSSA walR allele from JKD6004 replaced
walR in VISA strain JKD6005 (Figure 2C and 3).
In our previous studies using these VSSA and VISA clinical
pairs we had detected significant changes in a number of key
staphylococcal virulence mechanisms in VISA [4]. Most strikingly,
the VISA strains had marked reduction in agr activation despite
the absence of mutations in the agr locus. We measured expression
of RNAIII, the effector molecule of the agr locus, in the walKR
mutants during exponential growth phase (Figure 2F) and showed
that the mutations in either walK or walR had dramatic effects on
agr expression with minimal RNAIII expression in VISA strains or
the mutants harbouring the VISA walKR alleles compared to the
VSSA parents. Additionally, it has previously been demonstrated
using the Galleria mellonella model that clinical VISA has reduced
virulence compared to parent strains [30], however the genetic
basis for this has not been defined. Using this model the clinical
VISA strain JKD6008, and the walK mutant TPS3130 demon-
strated significantly reduced virulence compared to the parent
strain JKD6009 (Figure 4), indicating that WalKR also plays an
important role in control of virulence. The parent VSSA strain
JKD6004 was relatively avirulent in this model, therefore
significant changes in the clinical VISA (JKD6005) and the
mutant strain (TPS3190) were not observed.
While biofilm formation is reduced in some VISA strains, the
mechanisms underlying this have been unclear. We found that
mutations in walK and walR led to significant reduction in bioflm
formation that mimicked the changes seen in the clinical VISA
strains (Figure 2E). There was no significant difference in growth
rates of mutant and clinical strains to explain these findings.
Transcriptional Effects of WalK and WalR Mutations, and
Implications for WalKR Control of Central Metabolism
We next used microarray analysis to explore the global
regulatory effects of the walK (TPS3130) and walR (TPS3190)
mutants compared to the parent strains (Figure 5A, B; Table S1).
Any gene that demonstrated a fold change $1.5 accompanied by
an adjusted p-value of ,0.05 was included in the comparisons, and
this included 507 genes in the TPS3130 vs JKD6009 analysis and
334 genes in the TPS3190 vs JKD6004 analysis. An analysis of
genes that were significantly differentially regulated in the two
experiments, in the same direction, revealed 90 genes that were
down-regulated, and 73 genes that were up-regulated in WalKR
mutants compared to parent strains (Table S1 and Figure 5).
Three genes in S. aureus have been previously shown to have
upstream walR biding sites (orthologs in JKD6008 are
SAA6008_02607, isaA; SAA6008_02335, ssaA_1; SAA6008_
00250, lytM) [31], and six other genes involved in cell wall
Figure 1. Analysis of location of walKR mutations detected in study isolates. (A) Schematic figure of the walKR operon showing protein
domains and positions of identified mutations. Protein domains were defined according to Dubrac et al [25]. White regions of walK represent
membrane spanning regions. (B) Amino acid sequences of the walR and walK genes. Domains are highlighted in color according to figure 1A.
Identified mutations are indicated in bold type with an asterix. Membrane spanning regions of walK are italicized. The walR aspartic acid that is
phosphorylated by walK and the walK histidine in the HisKA domain that is autophosphorylated are shown by arrows. Conserved regions are
underlined and referred to in the text. (C) Ribbon diagram of the DNA binding domain of a WalR monomer from VISA strain JKD6005 (pink) modelled
against the 1.87 A ˚ structure of the WalR DNA-binding domain (PDB: 2ZXJ) from VSSA Staphylococcus aureus (blue). Shown is the position of the
substituted amino acid (K-.R) near the critical a3–b5 DNA binding loop (indicated by the arrow).
doi:10.1371/journal.ppat.1002359.g001
Table 4. Impact of mutations in WalKR on vancomycin and daptomycin susceptibility.
Isolate Description
Standard vanco
Etest (mg/mL)
Standard dapto
Etest (mg/mL)
Macro Etest
vanco 48hs (mg/mL)
Macro Etest teico
48hs (mg/mL)
Mutant set 1
JKD6009 Parent VSSA 1.5 0.19 4 6
JKD6008 Clinical VISA 4 0.5 12 16
JKD6208 JKD6009, GraS T136I 2 0.25 6 8
TPS3130 JKD6009, WalK G223D 3 0.25 8 16
TPS3128 JKD6009, GraS T136I and WalK G223D 4 0.75 12 16
Mutant set 2
JKD6004 Parent VSSA 1.5 0.5 4 6
JKD6005 Clinical VISA 4 2 8 12
TPS3124 JKD6005, WalR R208K (wildtype) from JKD6004 1.5 0.75 4 6
TPS3190 JKD6004, WalR K208R 4 2 8 12
Note: vanco, vancomycin; dapto, daptomycin; teico, teicoplanin; macro Etest uses a 2 McFarland inoculum.
doi:10.1371/journal.ppat.1002359.t004
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sequences, and have been shown to have increased expression
upon walKR induction in a mutant with inducible walKR activity
[32]. Unexpectedly, only two of these genes were differentially
regulated in both experiments. SAA6008_02607 (isaA) was up-
regulated in both experiments, 2.3-fold in TPS3190 compared to
parent and 6.2-fold in TPS3130 compared to parent, while
SAA6008_1007 (atl) was down-regulated in both experiments, 1.8-
fold (Table S1). Among 24 genes with predicted upstream WalR
binding sequences [31], only two were differentially regulated in
both our microarray experiments. These genes included
SA6008_00455 (ndhF) encoding an NADH dehydrogenase sub-
unit, which was up-regulated 2.2 to 2.4-fold, and SAA6008_02705
(sasF) encoding an LPXTG cell wall surface anchor protein, which
was down-regulated 2.8 to 3.7-fold.
While WalKR has been identified as a master regulator of cell
wall metabolism in S. aureus [25], the transcriptional profile of the
two mutant strains in this analysis painted a different picture of
WalKR control within the cell. The most dramatic and consistent
transcriptional changes were found in genes involved in central
metabolism. Using the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analysis (www.genome.jp) [33], the
major pathways where differential transcription occurred in both
mutants were genes whose products are involved in amino acid
metabolism (in particular alanine, aspartate, glutamate metabo-
lism [up-regulation of ald1, argG, argH; down-regulation of gltB,
gltD, SA6008_02661]; arginine and proline metabolism [up-
regulation of agrG, agrH, and down-regulation of aldA, ureA, ureB,
ureC]; valine, leucine and isoleucine metabolism [down-regulation
of ilvB, ilvC, ilvD]), in addition to significant up-regulation of genes
whose products are involved in purine and pyrimidine metabolism
(purF, purN, purM, purH, pyrC, pyrB, pyrAA, pyrR, pdp, tdk). In
contrast, only five out of 27 genes that have been consistently
grouped as part of the staphylococcal ‘‘cell wall stimulon’’ (sbtB,
vraS, sgtB, SA6008_01906, and SA6008_02595) [34–38] were
differentially regulated in the two experiments. All five of these
genes were down-regulated (1.6 to 3.6-fold) in the walKR mutant
compared to the parent strain.
The veracity of the microarray data was checked by quantitative
RT-PCR analysis of six genes from different pathways, including
argH, purF, pyrA, ureA, atl, and gltB. The qRT-PCR data was
consistent with the microarray results (Figure S2).
Discussion
Methicillin-resistance in S. aureus remains a significant public
health issue that is compounded by the evolution of strains with
low-level resistance to last-line agents such as vancomycin and
daptomycin. While the first VISA strain was reported in 1997 [5],
our understanding of the genetic determinants of VISA remains
incomplete. To address this issue we took a comparative genomics
approach that included whole genome sequencing of 10 clinical S.
aureus isolates, and showed that mutations within the essential
S. aureus regulatory locus walKR are important mediators of
intermediate vancomycin resistance. The contribution of both
walK and walR mutations to vancomycin resistance was experi-
mentally confirmed using bi-directional allelic exchange experi-
ments. By swapping walK and walR alleles between VSSA and
VISA strains we could make susceptible strains resistant and then
revert resistant strains to susceptible. In addition, consistently
observed features of VISA strains worldwide include cell wall
thickening and reduced autolytic activity [6-8,14,15], and analysis
of our walKR mutants showed the key role played by this locus in
VISA, as single nucleotide changes in either walK or walR led to
strains exhibiting these well-described VISA phenotypes.
Daptomycin is another cell wall active antibiotic with a different
mode-of-action to vancomycin but there is increasing data
demonstrating a link between VISA and daptomycin non-
susceptibility in S. aureus [10,19]. The clinical pairs of VSSA and
VISA used in this study were selected from patients that had been
treated with vancomycin, and not daptomycin. The vancomycin
induced walKR mutations led to an increase in daptomycin MIC in
clinical S. aureus, in some cases generating full daptomycin non-
susceptibility.WhilewalKmutationshavebeenpreviouslyassociated
with daptomycin non-susceptibility in association with mprF
mutations [20], no genetic manipulation of the walKR locus has
been performed to confirm the contribution of these mutations to
daptomycin resistance. Here we have shown for the first time the
contribution of mutations in walK or walR (without mprF mutations)
toreduced daptomycin susceptibility.Interestingly,the combination
of the graS (T136I) and walK (G223D) mutation in JKD6008 was
associated with a higher daptomycin MIC than either mutation
alone (Table 4), suggesting an additive effect of these two mutations
to increase both vancomycin and daptomycin resistance.
WalKR is highly conserved and specific to low GC gram-
positive pathogens [25], and is the only known essential two
Table 5. Summary of genomic differences between S. aureus TPS3130 versus JKD6009 and JKD6008.
No
Location
(JKD6008) Strain/SNP
a
Locus_tag/annotation/comment
JKD6000
(VSSA)
JKD6008
(VISA)
TPS3130
(VISA)
1. 25769 GGT GAT GAT SAA6008_00019. Sensor histidine kinase, WalK. Targeted allele swap in TPS3130, G223D.
2. 360905
b GCTG C CG C G SAA6008_00313. Putative glycerol-3-phosphate transporter, GlpT. Silent mutation, same as JDK6008.
3. 517284
c AAabsent SAA6008_00478. PTS system trehalose-specific IIBC component, pseudogene. ‘A’ deletion in TPS3130
corrects frame-shift mutation found in JKD6009 and JKD6008.
4. 803235
c GAA GAA GGA SAA6008_00741. Putative lipid kinase. Predicted amino acid change in TPS3130, E225G. Different to
JKD6008 and JKD6009.
5. 2470905
b CCT TCT TCT SAA6008_02357. Sodium/bile acid symporter family protein. Predicted amino acid change in TPS3130,
P128S. Same as JKD6008.
aAll mutations checked in all strains by PCR and Sanger sequencing.
bIndicates potential compensatory mutation accompanying the introduced walK mutation.
cMutation only present in TPS3130.
doi:10.1371/journal.ppat.1002359.t005
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PLoS Pathogens | www.plospathogens.org 8 November 2011 | Volume 7 | Issue 11 | e1002359Figure 2. Analysis of antibiotic susceptibility, autolytic activity, biofilm formation and agr activity of clinical and mutant strains. (A)
and (B) Vancomycin population analysis results demonstrate increased resistance in strains containing walK or walR mutations. (C) and (D) Autolytic
activity for clinical and mutant strains demonstrates reduced autolytic activity in strains containing walK or walR mutations. All results are expressed
as mean 6 SEM for at least 3 biological replicates. (E) Biofilm analysis of clinical and mutant strains using a 96-well plate biofilm assay. The presence of
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studied in B. subtilis, S. aureus and S. pneumoniae where cell wall
metabolism genes dominate the predicted regulon of WalR [25]. A
high frequency of walKR mutations was detected in this study, with
mutations in eight of the 10 VISA, and two of the three hVISA
strains tested, suggesting that mutations within this locus are a
previously under-appreciated mediator of VISA. Our findings are
supported by recent data from Shoji et al who found walK
mutations were common in an international collection of VISA
strains, although no walR mutations were reported [41]. While
much attention has been focussed on the role of vraRS and graRS
mutations in VISA [12,13,18,41] none of the five sequenced
strains in our study contained a vraRS mutation, and only one
strain (JKD6008) contained a previously recognized graS mutation
[18], suggesting these regulators are not the dominant mediators of
VISA. It is unclear if there is a clone-specific pathway to VISA,
such that we may have uncovered a frequent pattern of walKR
mutation because we sequenced ST239 strains of S. aureus, the
dominant hospital clone from our region. We attempted to address
this potential bias by including a global collection of VISA isolates
that were available to us for testing, and included non-ST239
strains. It is notable then that all three ST5 VISA strains tested
also contained a walK mutation, however the ST247 strains and
one of the ST239 strains did not contain walKR mutations, nor
mutations in the downstream negative regulators of walKR, yycHIJ.
Mutations of potential interest in the strain JKD6051 that is the
only fully sequenced strain not to contain a walKR mutation
included a mutation in the regulator sarR (A68T), and a mutation
in rpoB (H481Y). There has been recent interest in the role of rpoB
mutations in VISA, with the demonstration that an A621E amino
acid change in RpoB leads to the hVISA phenotype [17], and
more recently a link demonstrated between rifampicin resistance
in S. aureus (due to rpoB mutations) and hVISA [42]. Therefore it is
possible that the rpoB mutation detected in JKD6051 contributed
to the VISA phenotype, however this was not specifically tested in
this study.
Whole genome analysis of the allelic exchange VISA mutant
TPS3190 using Ion Torrent sequencing confirmed the absence of
any significant additional mutations in this laboratory derived
strain, in particular an absence of agr mutations that might
otherwise explain some of the described phenotypes. The
sequencing of TPS3130 revealed a more complex story, with the
detection of four additional SNPs, two of which were also present
in the clinical VISA strain JKD6008 (Table 5). WalKR is thought
to control cell-wall metabolism through sensing the lipid-II
intermediate during peptidoglycan biosynthesis and regulating
autolysin gene expression in this organism [25], however the basis
for its essentiality is not well understood but appears to be at least
partly related to WalKR control of cell wall metabolism [40]. It is
therefore likely that S. aureus is very sensitive to changes in walKR
because of its essential nature. We propose that the modification of
walK in JKD6008 (and TPS3130) has been accompanied by at
least two compensatory mutations. Both of these SNPs have
occurred in genes linked to substrate transport. A deeper
understanding of the role of WalKR will be required before we
can say how the changes we observed in JKD6008 and TPS3130
might compensate for a mutation in walK. The two additional
TPS3130-specific changes are equally intriguing and may also be
compensatory, with a nucleotide deletion that corrects a frame-
walK or walR mutations significantly reduces biofilm formation compared to parental strains, mimicking the impact of the VISA phenotype on biofilm
formation. All results are expressed as mean 6 SEM for at least 3 biological replicates. Statistical analysis was performed comparing VISA and mutant
strains to the parental strains JKD6009 or JKD6004 (** p,0.01; *** p,0.001). (F) Analysis of agr activity of clinical and mutant strains by real time
quantitative PCR of the effector molecule RNAIII. Results are presented relative to the parental strain JKD6009 or JKD6004 which has been normalized
to 1. All results are expressed as mean 6 SEM for at least 3 biological replicates.
doi:10.1371/journal.ppat.1002359.g002
Figure 3. Cell wall thickness of clinical and walKR mutant
strains. Representative electron microscopic images of parental and
mutant S. aureus cells. The mean cell wall thickness for each strain is
included, based on at least 100 measurements of the cell wall. Statistical
analysis of cell wall thickness was performed compared to the parent
strains JKD6009 or JKD6004. Note, *** p,0.001; ** p,0.01.
doi:10.1371/journal.ppat.1002359.g003
Figure 4. Galleria mellonella virulence analysis of clinical and
walK mutant strains. Virulence analysis using the Galleria mellonella
model demonstrating percent survival over 6 days using a Kaplan Meier
plot. The parent VSSA strain JKD6009, the clinically derived VISA
JKD6008, and the laboratory derived mutant TPS3130 are included.
Included also for comparison is the virulent community clone of
methicillin-resistant S. aureus, USA300. The difference in survival
between JKD6009 and JKD6008 or TPS3130 was statistically significant
(p,0.0001).
doi:10.1371/journal.ppat.1002359.g004
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group translocation phosphate transporter and a predicted amino
acid change in a hypothetical gene with a putative lipid kinase
domain (Table 5).
Two key questions arising are how do mutations in walKR
influence function of the regulator, and then cause VISA.
Mwangi et al reported a mutation in the downstream negative
regulator of WalKR, yycH that was associated with an increase in
vancomycin resistance in a series of clinical isolates. It was
predicted that this mutation would increase WalKR activity by
reducing negative feedback to the regulator [11]. In another
study, an IS256 insertion into the walKR promoter region was
associated with a change in vancomycin resistance, and the
authors predicted that a hybrid, overactive promoter was
responsible for increased walKR expression and resistance [43].
In the present study, however, we found a range of SNPs across
all the functional domains of WalKR in VISA strains, leading us
to propose that decreased WalKR performance is probably the
more likely consequence of these changes and that the VISA
phenotype is initiated by a reduction in WalKR activity. WalKR
has also been shown to positively regulate genes encoding
enzymes with cell wall lytic activity. The reduction in autolytic
activity and attenuated biofilm formation of the walKR mutants in
this study also suggest that the mutations are restricting WalKR
function, as these phenotypes have been previously demonstrated
to occur in a conditional mutant with reduced WalKR activity
[32]. We have also recently described a similar phenomenon
where a point mutation in another essential S. aureus gene (relA)
contributed to a reduction in function of the enzyme, but not
complete absence of activity [44].
To further investigate the contribution of the walK and walR
mutations to resistance we performed a global transcriptional
profile of the mutant strains compared to parent strains
(Figure 5). We were surprised to find a relative paucity of cell
wall metabolism genes represented in the transcription expres-
sion data. We intentionally used a low fold cut off of 1.5 for
Figure 5. Microarray transcriptional analysis of defined WalK (G223D) and WalR (K208R) mutants compared to parental strains. (A)
Results of microarray transcriptional analysis of TPS3130 (WalK G223D) and TPS3190 (WalR K208R) compared to respective parental strains. Up-
regulated genes (in red) are differentially up-regulated in the mutants compared to the parent strains, and the down-regulated genes (in green) are
differentially down-regulated in the mutant strains compared to parent strains. The heat map analysis highlights the proportion of each cluster of
orthologous groups (COG) functional group [61] that is differentially regulated in the array analysis. This clearly demonstrates significant global
transcriptional changes in the WalK and WalR mutant strains affecting genes from all COG groups, and providing a similar pattern of transcriptional
response. (B) Schematic representation of the genes commonly transcribed in the two microarray experiments. A total of 163 genes were commonly
transcribed, and the major up-regulated and down-regulated genes are highlighted. Note, # denotes loci which have been previously shown or are
predicted to have upstream WalR binding domains [31,32]; A, alanine; D, aspartate; E, glutamate; R, arginine; P, proline; V, valine; L, leucine; I,
isoleucine.
doi:10.1371/journal.ppat.1002359.g005
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despite this we only found four genes that were differentially
expressed in both experiments that have been previously
predicted to be part of the WalR regulon [31,32]. While
d o w n - r e g u l a t i o no fm a j o ra u t o l y s i ne x p r e s s i o n( atl)w a sd e t e c t e d
(1.8-fold in both mutants) and this could potentially explain the
changes in autolytic activity detected in WalK and WalR
mutants (Figure 2), the dominant theme of the transcriptional
profiles was a change in transcription of genes encoding
products involved in selected aspects of central metabolism.
For example, pathway analysis based on our microarray data
suggests WalKR interacts directly or indirectly with several
components of the urea cycle. So while cellular metabolism in
the mutants has been shifted away from anabolism of branched
chain amino acids (valine, leucine and isoleucine), metabolites
within the urea cycle, including glutamine, arginine and
aspartate, have gained more prominence, with up-regulation
of genes encoding enzymes that could increase yields of
substrates that feed purine and pyrimidine biosynthesis. An
increase in pyrimidine metabolism would tie in neatly with the
observed increased cell wall thickness and decreased capsular
polysaccharide in the walKR mutant strains. Two distinct
pathways are used by S. aureus to synthesise UDP N-
acetylglucosamine (UDP-GlcNAc), a key intermediate for both
peptidoglycan and capsular polysaccharide biosynthesis. Pools
of UDP-GlcNAc for peptidoglycan biosynthesis are produced by
glycolysis and pyrimidine metabolism while UDP-GlcNAc for
capsule biosynthesis is linked to gluconeogenesis and aminosu-
gar metabolism [45]. Therefore an increase in pyrimidine
metabolism might be predicted to increase pools of UDP-
GlcNAc available for peptidoglycan synthesis, with a concom-
itant decrease in the availability of the same metabolite for
capsule production.
Finally, this study has demonstrated a link between walKR
mutations and a number of VISA associated phenotypes. While
biofilm formation is reduced in some VISA strains, including
those previously characterized str a i n su s e di nt h i ss t u d y[ 1 5 ] ,t h e
mechanisms underlying this have been unclear. We found that
mutations in walK and walR led to significant reduction in
biofilm formation that mimicked the changes seen in the VISA
strains (Figure 2E). Reduced walKR activity in a conditional
mutant was previously associated with reduced biofilm produc-
tion [32], and is consistent with the changes in biofilm formation
seen with S. aureus mutants deficient in autolysis [46,47].
Extracellular DNA (eDNA) that is released by autolysis is an
important initial step in S. aureus biofilm formation [48]. We
propose that there may be an absence of eDNA in VISA and
that this may explain the biofilm defect observed in VISA strains
with walKR mutations. The agr l o c u si saq u o r u ms e n s i n gt o x i n
regulatory system that is critical to S. aureus virulence [49]. Using
real time RNAIII PCR and microarray transcriptional analysis
we have demonstrated that mutation of walKR is associated with
reduced agr activation during exponential growth, however it is
unclear if this is a direct or indirect relationship. Little is known
about the role WalKR plays in S. aureus virulence. While
virulence studies have been performed using streptococcal
species, the impact of walK mutants in these experiments has
been conflicting [50,51]. Using the invertebrate model Galleria
mellonella a significant attenuation of virulence of the walK
mutant strain TPS3130 was demonstrated (Figure 4). However,
because there was no difference in the virulence of the clinical
pair JKD6004/JKD6005, no impact of the walR mutation in the
parental strain was discernable.
In conclusion, this study highlights the potential for single
nucleotide changes in S. aureus to dramatically affect bacterial
behaviour and antimicrobial resistance. Complete bacterial genome
sequencing of carefully selected strains has revealed mutations in
walKR as a common mechanism for in vivo evolution of multi-drug
resistance in this pathogen, leading to daptomycin cross-resistance,
and impacting virulence mechanisms of the organism. Additionally,
transcription profiling of strains with single base substitutions in
walK or walR indicate that this regulatory locus not only controls
autolysis, but more generally impacts metabolic activities within the
cell. Efforts to design therapeutic strategies based on inhibiting
walKR should be aware of the potential impact on the organism of
inducing mutations in this locus.
Table 6. Laboratory strains, mutant strains, and plasmids used in study.
Strain or Plasmid Features Reference
Laboratory Strains
RN4220 (S. aureus) S. aureus strain capable of maintaining shuttle plasmids [63]
E. coli DH5alpha NEB
Mutant Strains
JKD6208 JKD6009 with graS point mutation from VISA JKD6008, resulting in T136I mutation [18]
TPS3128 JKD6208 with walK mutation from VISA JKD6008, resulting in G223D mutation (double mutant – graS and walK) This study
TPS3130 VSSA JKD6009 with walK mutation from VISA JKD6008, resulting in G223D mutation This study
TPS3124 VISA JKD6005 with wildtype walR allele from VSSA JKD6004 This study
TPS3190 VSSA JKD6004 with walR point mutation from VISA JKD6005, resulting in K208R mutation This study
USA300 (FPR3757) Clinical strain of ST8 clone USA300 [64]
Plasmids
pKOR1 E. coli - S. aureus shuttle vector [65]
pTPS6004 pKOR1 with walR allele from JKD6004, region for recombination generated with oligos 1901 and 1908 This study
pTPS6005 pKOR1 with walR allele from JKD6005, region for recombination generated with oligos 1901 and 1908 This study
pTPS6008 pKOR1 with walK allele from JKD6008, region for recombination generated with oligos 1901 and 1908 This study
doi:10.1371/journal.ppat.1002359.t006
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Strains and Growth Conditions
Bacterial strains and a description of their antibiotic suscepti-
bility, geographical origin, and plasmids used in the study are listed
in Tables 1 and 6. Staphylococcal strains were stored in glycerol
broth at 280uC and subcultured twice onto Horse Blood Agar
(Oxoid) before being used for any experiment. Unless otherwise
indicated all S. aureus isolates were grown in BHIB (Oxoid), and E.
coli grown in LB broth (Oxoid). When required media was
supplemented with the following antibiotics at the indicated
concentrations: for E. coli, ampicillin 100 mg/ml; for S. aureus
RN4220, chloramphenicol 10 mg/ml; for S. aureus clinical isolates,
chloramphenicol 25 mg/ml.
Antibiotic Susceptibility and Molecular Typing
Vancomycin MICs were determined by microbroth MIC
according to CLSI criteria [52], and VISA defined as a strain
with a vancomycin broth MIC of 4–8 mg per ml [52]. Detection of
heterogenous-VISA (hVISA) was performed by Etest GRD
according to recommendations of the manufacturer, while clinical
and mutant strain pairs were tested by Macro method Etest using
a 2 McFarland inoculum [3]. Daptomycin MICs were performed
by Etest (AB Biodisk), according to manufacturer’s instructions,
and isolates were defined as daptomycin non-susceptible according
to CLSI criteria (daptomycin MIC .1 mg per ml) [52]. Clinical
isolates underwent molecular characterisation using the DNA
microarray StaphyType96 (CLONDIAG, Jena, Germany). DNA
extraction was performed using the DNeasy Tissue Kit (Qiagen,
Hilden, Germany), and the microarray and data analysis were
performed as previously described [53]. The DNA microarray
assigns strains to clonal complexes (CC) using reference strains
previously defined by multilocus sequence typing (MLST) and spa
typing. Pulsed-field gel electrophoresis using SmaI enzyme
restriction was performed using the CHEF DR III system
(BioRad, Berkeley, California) to confirm clonal group if necessary
[54].
DNA Methods, Molecular Techniques and Construction
of Mutants
Standard procedures were used for DNA manipulation,
molecular techniques, PCR, sequencing and plasmid extraction.
To generate walK and walR mutants, allelic replacement
experiments were performed using the vector pKOR1, as
described previously [18]. The locus containing the walKR
mutation was amplified from JKD6008, JKD6004, and
JKD6005 for exchange into the respective parental strains using
primers 1901 and 1908 (Table S2). The amplified product was
cloned into the attB sites of pKOR1 and then transformed into E.
coli DH5alpha. After transformation into E. coli, pKOR1 with the
integrated walKR locus was extracted and sequenced to confirm
the correct sequence, prior to performing allelic exchange in
RN4220 intermediate and the clinical S. aureus strain. To confirm
that no other significant mutations were introduced during the
homologous recombination, the whole walKR locus was sequenced
from the mutant strains using oligonucleotides covering the whole
replaced sequence and its flanking ends (Table S2).
High Throughput DNA Sequencing
Genome sequences for four ST239 VSSA and VISA clinical
pairs (VSSA: JKD6000, JKD6004, JKD6021 and JKD6052;
VISA: JKD6001, JKD6005, JKD6023, and JKD6051) were
obtained from an Illumina Genome Analyzer II using 36-cycle
paired-end chemistry. SOLiDv2 26 bp mate-pair sequencing was
also performed on the clinical VSSA strain JKD6009, for which
previous 454 GS20 shotgun sequence data was available. Single-
end genome sequencing of the two laboratory-induced mutants
TPS3130 and TPS3190 was performed using Ion Torrent
sequencing as described [55]. TPS3130 yielded 88.7 Mbp from
four 314 chips and TPS3190 yielded 56.9 Mbp from two 314
chips.
Comparative Genomics
A read mapping approach was used to compare the sequences
from the four VSSA/VISA clinical pairs described above, the
previously described clinical pair JKD6009/JKD6008 (NCBI
Genbank accession numbers NZ_ABSA00000000 and
CP002120) and the Ion Torrent sequences from TPS3130 and
TPS3190. The reads from all genomes were aligned to the
JKD6008 reference using SHRiMP 2.0 [56]. SNPs were identified
using Nesoni v0.52, which uses the aligned reads of each genome
to the reference to construct a tally of putative differences at each
position, including substitutions, insertions, and deletions [www.
bioinformatics.net.au]. This tally was input to a Bayesian model to
decide whether a base (or deletion) could be called for the position,
and if so, whether it differed from the reference. Each position is
treated as possibly containing a mixture of bases. A particular base
is called if the likelihood that it makes up more than 50% of the
mixture exceeds a threshold, set to 0.99 by default. This likelihood
is calculated by updating a prior distribution over all possible
mixtures, in the form of a Dirichlet distribution, as bases are
observed. A similar procedure is used to call the presence or
absence of insertions between positions in the reference. Using the
whole genome sequence of JKD6008 as a reference a global SNP
analysis was performed, and allelic variability at any nucleotide
position was tallied to generate a global SNP analysis for every
genome compared to JKD6008. Protein modelling was performed
using the crystal structure of the WalR DNA-binding domain of S.
aureus (PDB structure: 2ZXJ) using ModBase [27,57].
Phenotypic Assays
Biofilm and autolytic assays were performed as described
previously [15]. Cell wall thickness was measured by taking 100
readings of wall thickness per strain from multiple cells after
preparation of electron microscopic images as described previously
[15].
Galleria mellonella Virulence Assay
This invertebrate S. aureus infection model was used to study the
virulence of clinical and mutant strains as previously described
[44]. Briefly, a HPLC syringe was used to inject 10 mL of bacterial
suspension (approx 1.0610
6 CFU) into the last left proleg of each
caterpillar. Bacterial colony counts were performed to confirm
consistency of inoculum, and caterpillars monitored daily for 6
days. Multiple biological replicates were performed for each strain.
Microarray Transcriptional Analysis
Microarray transcriptional analysis was performed with TIGR
version 9 S. aureus arrays, as previously described [4]. For
preparation of total RNA shaking flasks (50 mL BHI broth in
250 mL flasks) were inoculated with 500 mL overnight BHI broth
culture and incubated on a 225rpm shaker at 37uC. Optical
density was closely monitored, and one millilitre of sample was
collected at exponential growth phase (optical density at 600 nm of
0.5) and 0.5 mL RNA stabilization reagent (RNA later, Qiagen)
was added and mixed immediately. The mixture was allowed to
stand in room temperature for 10 minutes before total RNA was
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and hybridisations were performed on four different occasions,
and the dye swapped with each biological replicate. The images
were combined and quantified and then imported into BASE and
analyzed using Bioconductor and Limma [58,59]. The fold ratio
of gene expression for the mutant strains TPS3130 and TPS3190
relative to the parental MRSA strain JKD6009 and JKD6004,
respectively, were calculated. Using a modified t-test p values were
calculated and adjusted for multiple testing using false discovery
rate (FDR) correction. A $ 1.5-fold change with p,0.05 was
considered significant.
Quantitative RT-PCR
To investigate activity of the agr locus (RNAIII) and confirm the
microarray transcriptional results qRT-PCR was performed for
RNAIII, argH, purF, pyrA, ureA, atl, and gltB, using oligos in Table
S2. RNA was prepared from exponential phase cultures as
previously described [15]. Two on-column DNase I digestion steps
were performed and cDNA synthesis using SuperScript II RNase
H reverse transcriptase (Invitrogen) included a SuperScript II
negative control to confirm the absence of genomic DNA. Relative
expression was determined as previously described [15], and was
normalised against gyrB as previously described [60]. Results were
obtained from 3 biological replicates each performed in triplicate.
Statistical Analysis
Statistical analyses of mutant strains were performed using the
two-tailed Mann Whitney U test, with a p,0.05 set for statistical
significance. Kaplan Meier plots of G. mellonella killing results were
analyzed using the log rank test. All analyses were performed using
Prism for Macintosh ver 5.0 (GraphPad Software Inc., CA, USA)
Accession Numbers
For the sequenced clinical strains JKD6000, JKD6001,
JKD6004, JKD6005, JKD6009, JKD6021, JKD6023, JKD6051,
JKD6052 the reads have been deposited in the NCBI Sequence
Read Archive under study accession number SRA027352. The
Ion Torrent reads for the mutant strains TPS3130 and TPS3190
have been deposited in the NCBI Sequence Read Archive under
study accession number SRA044879.2. Microarray data has been
submitted to GEO with accession number GSE29157. Protein
modelling was performed using the crystal structure of the WalR
DNA-binding domain of S. aureus (PDB structure: 2ZXJ).
Supporting Information
Figure S1 Results of Ion Torrent sequencing of mutant strain
TPS3130. (A) Non-ambiguous read mapping of Ion Torrent
sequences for TPS3130 against the whole genome sequence of
reference strain JKD6008, demonstrating genome coverage and
depth (repeat regions excluded). (B) Detailed analysis of the read
coverage results for the walKR operon confirms the presence of the
G to A mutation at position 25769 in the reference strain
JKD6008 and the mutant TPS3130.
(TIF)
Figure S2 Quantitative real-time PCR confirmation of micro-
array results. Using qRT-PCR the fold ratio of gene expression for
the mutant strain (TPS3130 or TPS3190) was compared to the
parent strain (JKD6009 or JKD6004) for six genes (argH, purF,
pyrA, ureA, atl and gltB). qRT-PCR results are presented as mean 6
SEM for at least 3 biological replicates. Microarray expression
results for the same genes also shown.
(TIF)
Table S1 List of differentially regulated genes common to the
WalK (TPS3130) and WalR (TPS3190) mutants generated in this
study compared to parental strains, based on global microarray
transcriptional analysis.
(PDF)
Table S2 List of primers used in this study.
(DOCX)
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